Spiral Therapeutics Closes $8.25M in Financing
- Spiral Therapeutics, a South San Francisco, CA-based clinical-stage company focused on delivering therapies for inner ear disorders, raised $8.25M in funding
- The round was led by Savoir Capital and Catalio Capital Management with participation from Humboldt Fund, Savoir Capital and Catalio Capital Management
- The company intends to use the funds for the continuing development of its lead candidate, SPT-2101, for the treatment of inner ear inflammation
- The company is a clinical-stage company focused on delivering therapies for inner ear disorders
- Its novel drug delivery platform allows for minimally invasive, precise and durable exposure of drugs to the cochlea
